These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 17098957)
21. Treating dyslipidaemia in the setting of diabetes mellitus and cardiovascular disease: another focus. Tahrani AA Int J Clin Pract; 2006 Nov; 60(11):1515; author reply 1515-6. PubMed ID: 17073848 [No Abstract] [Full Text] [Related]
22. Fenofibrate and cardiovascular risk: a synopsis and commentary on (FIELD). Bailey CJ Diabet Med; 2006 Feb; 23(2):109-12. PubMed ID: 16433706 [No Abstract] [Full Text] [Related]
23. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study. Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548 [TBL] [Abstract][Full Text] [Related]
24. After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate. Sacks FM Am J Cardiol; 2008 Dec; 102(12A):34L-40L. PubMed ID: 19084088 [TBL] [Abstract][Full Text] [Related]
25. Role of the pharmacist. Bottorff M Pharmacotherapy; 2006 Dec; 26(12 Pt 2):227S-232S. PubMed ID: 17125450 [TBL] [Abstract][Full Text] [Related]
26. Is it time to stop treating dyslipidaemia with fibrates? Benatar JR; Stewart RA N Z Med J; 2007 Sep; 120(1261):U2706. PubMed ID: 17853928 [TBL] [Abstract][Full Text] [Related]
27. The current unmet need in type 2 diabetes mellitus: addressing glycemia and cardiovascular disease. Levy P Postgrad Med; 2009 May; 121(3 Suppl 1):7-12. PubMed ID: 19494472 [TBL] [Abstract][Full Text] [Related]
28. [Prevention of ischemic cardiovascular complications in type 2 diabetes]. Moulin P Journ Annu Diabetol Hotel Dieu; 2000; ():125-37. PubMed ID: 10932875 [No Abstract] [Full Text] [Related]
29. Interpreting clinical trials of diabetic dyslipidaemia: new insights. Wierzbicki AS Diabetes Obes Metab; 2009 Mar; 11(3):261-70. PubMed ID: 17645560 [TBL] [Abstract][Full Text] [Related]
30. ADVANCE trial of great importance in preventing cardiovascular deaths in type 2 diabetes. Cardiovasc J Afr; 2007; 18(5):343-4. PubMed ID: 17985038 [No Abstract] [Full Text] [Related]
31. Therapy and clinical trials. Usman M; Peter R Curr Opin Lipidol; 2006 Oct; 17(5):612-4. PubMed ID: 16960511 [No Abstract] [Full Text] [Related]
32. Introductory remarks. Velasco M; Bermúdez V; Israili ZH; Hernández-Hernández R Am J Ther; 2010; 17(3):236. PubMed ID: 20479578 [No Abstract] [Full Text] [Related]
33. Bezafibrate reduces the incidence of type 2 diabetes mellitus in patients with obesity. Miller M Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):198-9. PubMed ID: 16932284 [No Abstract] [Full Text] [Related]
34. FIELD study. Rees A Diabet Med; 2006 Jul; 23 Suppl 3():6-12. PubMed ID: 16805876 [No Abstract] [Full Text] [Related]
35. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease. Staels B; Maes M; Zambon A Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):542-53. PubMed ID: 18628776 [TBL] [Abstract][Full Text] [Related]
36. Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus. Steiner G Am J Cardiol; 2008 Dec; 102(12A):28L-33L. PubMed ID: 19084087 [TBL] [Abstract][Full Text] [Related]